Literature DB >> 20404552

Downregulation of voltage-dependent anion channel-1 expression by RNA interference prevents cancer cell growth in vivo.

Inbar Koren1, Ziv Raviv, Varda Shoshan-Barmatz.   

Abstract

The voltage-dependent anion channel 1 (VDAC1), located at the outer mitochondrial membrane (OMM), is a key protein in regulating the exchange of ions, nucleotides and a variety of metabolites in and out of the mitochondria. As such, VDAC serves a crucial role in cellular energy maintenance. We have previously shown that silencing VDAC1 expression in T-Rex-293 cells by means of RNA interference using shRNA directed to human (h)VDAC1 resulted in reduced ATP production and a decrease in cell growth. Since cancer cells highly express VDAC, we examined here the effects of shRNA-hVDAC1-mediated silencing of VDAC1 expression on cancer cell growth in an animal model. To this end, HeLa cervical cancer cells were stably transfected with an inducible shRNA plasmid encoding for a sequence directed to hVDAC1. VDAC1 expression in these cells was decreased almost completely. Stably transfected shRNA-hVDAC1 HeLa cells proliferated much slower than did control cells, pointing to VDAC1 expression as being essential for normal growth of HeLa cancer cells. We further studied the ability of hVDAC1 silencing to block cancer cell proliferation in vivo. Nude mice subcutaneously inoculated with stably transfected shRNA-hVDAC1 HeLa cells developed about 40-fold smaller tumors than did mice inoculated with control HeLa cells. Taken together, the results of this study demonstrate, for the first time, the anticancer therapeutic potential of VDAC1 downregulation by means of shRNA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404552     DOI: 10.4161/cbt.9.12.11879

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  24 in total

1.  Voltage dependent anion channel-1 (VDAC-1) as an anti-cancer target.

Authors:  Saroj P Mathupala; Peter L Pedersen
Journal:  Cancer Biol Ther       Date:  2010-06-21       Impact factor: 4.742

2.  Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks.

Authors:  Swaroop Kumar Pandey; Renen Machlof-Cohen; Manikandan Santhanam; Anna Shteinfer-Kuzmine; Varda Shoshan-Barmatz
Journal:  Biomolecules       Date:  2022-06-27

3.  MicroRNA-7 downregulates the oncogene VDAC1 to influence hepatocellular carcinoma proliferation and metastasis.

Authors:  Feiran Wang; Yong Qiang; Lirong Zhu; Yasu Jiang; Yinda Wang; Xian Shao; Lei Yin; Jiahui Chen; Zhong Chen
Journal:  Tumour Biol       Date:  2016-01-30

4.  VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.

Authors:  Tasleem Arif; Yakov Krelin; Itay Nakdimon; Daniel Benharroch; Avijit Paul; Daniela Dadon-Klein; Varda Shoshan-Barmatz
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

5.  VDAC1: from structure to cancer therapy.

Authors:  Varda Shoshan-Barmatz; Dario Mizrachi
Journal:  Front Oncol       Date:  2012-11-29       Impact factor: 6.244

6.  Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer.

Authors:  Claire Grills; Puthen V Jithesh; Jaine Blayney; Shu-Dong Zhang; Dean A Fennell
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

7.  Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo.

Authors:  Tasleem Arif; Lilia Vasilkovsky; Yael Refaely; Alexander Konson; Varda Shoshan-Barmatz
Journal:  Mol Ther Nucleic Acids       Date:  2014-04-29       Impact factor: 10.183

8.  Expression profiling of mitochondrial voltage-dependent anion channel-1 associated genes predicts recurrence-free survival in human carcinomas.

Authors:  Jae-Hong Ko; Wanjun Gu; Inja Lim; Tong Zhou; Hyoweon Bang
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

9.  Clinical implication of voltage-dependent anion channel 1 in uterine cervical cancer and its action on cervical cancer cells.

Authors:  Chih-Hsien Wu; Yu-Wen Lin; Tzu-Fan Wu; Jiunn-Liang Ko; Po-Hui Wang
Journal:  Oncotarget       Date:  2016-01-26

10.  Cyclophilin 40 alters UVA-induced apoptosis and mitochondrial ROS generation in keratinocytes.

Authors:  Jana Jandova; Jaroslav Janda; James E Sligh
Journal:  Exp Cell Res       Date:  2012-12-03       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.